Recent News

• 04.17.2025 - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.17.2025 - Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 04.07.2025 - Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
• 04.07.2025 - Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
• 03.20.2025 - Martin Fan, Ph.D.
• 03.20.2025 - Martin Fan, Ph.D.
• 03.17.2025 - Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
• 03.17.2025 - Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
• 02.05.2025 - Guggenheim SMID Cap Biotech Conference
• 02.05.2025 - Guggenheim SMID Cap Biotech Conference

Recent Filings

• 04.01.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 03.21.2025 - 3 Initial statement of beneficial ownership of securities
• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.11.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.05.2025 - 8-K Current report
• 02.05.2025 - EX-99.1 EX-99.1